Key Highlights

  • First patient dosed with ALA-101 in the SAPPHIRE phase 1 clinical trial (NCT07518329) at The Alfred hospital in Melbourne under lead investigator Dr Sam Fiorenza
  • ALA-101 is an allogeneic, off-the-shelf CD19 CAR-iNKT cell therapy targeting relapsed or refractory CD19-positive non-Hodgkin lymphoma and leukaemia
  • The SAPPHIRE study is a multi-centre, open-label, dose-escalation and expansion trial; initial safety and efficacy data are expected in early CY2027
  • The therapy uses healthy donor-derived iNKT cells, bypassing the costly and time-consuming Manufacturing process required for conventional autologous CAR-T therapies

Arovella Therapeutics Limited (ASX: ALA), the Melbourne-based clinical-stage biotechnology company, announced on 27 October 2026 that the first patient had been dosed with ALA-101 in its first-in-human phase 1 clinical trial, marking a significant transition from preclinical development to the bedside for what the company describes as a novel class of off-the-shelf cell therapy for blood cancers.

The SAPPHIRE study — formally identified as ALA-101-001 and registered under clinical trial identifier NCT07518329 — is an open-label, multi-centre, dose-escalation and expansion trial evaluating ALA-101 in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and leukaemia. The first patient received ALA-101 at The Alfred, a major academic hospital in Melbourne, following standard lymphodepleting chemotherapy and under the supervision of lead investigator Dr Salvatore (Sam) Fiorenza.

The Off-the-Shelf Advantage in Cell Therapy

The defining characteristic of ALA-101 — and the commercial thesis that underpins Arovella's development program — is its allogeneic, off-the-shelf nature. Conventional CAR-T cell therapies are autologous, meaning they are manufactured from each individual patient's own cells. This process involves extracting the patient's T cells, engineering them in specialised facilities, and returning them to the patient weeks later. The process is expensive, logistically complex, and critically, it is not available to patients who are too unwell to have their cells collected or whose own cells are of insufficient quality after prior treatments.

ALA-101 is derived instead from healthy donor cells — specifically, invariant natural killer T (iNKT) cells — which are engineered and manufactured in advance and can be stored and deployed when a patient needs treatment. Chairman David Williams described the technology as a "game changer," noting that the current treatment approach requires a patient's own cells, a process that is costly and time-consuming, whereas ALA-101 is manufactured and sitting on a shelf ready for use.

The technology underlying ALA-101 is licensed from Imperial College London, providing Arovella with an academic foundation for its development program.

SAPPHIRE Trial Design and Near-Term Data Expectations

The initial dose escalation phase of the SAPPHIRE trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of a single dose of ALA-101. Dosing during the escalation phase will be staggered in accordance with regulatory requirements as part of Investigational New Drug (IND) approval, ensuring adequate safety review between patients. The trial is being conducted across multiple centres, and initial data are expected to be available in early CY2027.

Acting Chief Executive Officer Dr Nicole van der Weerden described the first patient dosing as "the culmination of several years of focused scientific, manufacturing, regulatory and clinical development," and noted that the trial will provide important insights into the safety, expansion, persistence, and B cell-depleting activity of ALA-101. The company views these data as supportive of the broader CAR-iNKT platform across blood cancers, solid tumours, and autoimmune diseases.

Lead investigator Dr Sam Fiorenza observed that many patients with relapsed or refractory B cell malignancies either relapse following standard therapies or are unable to access currently available autologous CAR-T treatments, framing ALA-101 as a potential solution to an unmet medical need in a difficult-to-treat patient population.

Sector Context: Allogeneic Cell Therapy Remains a Competitive Frontier

The allogeneic cell therapy space is attracting significant global Investment and scientific attention. Several large-cap pharmaceutical and biotechnology companies are developing off-the-shelf alternatives to autologous CAR-T, and the field has seen a mix of promising early-stage data and setbacks in later-stage trials. The commercial prize is substantial — the global CAR-T market is projected to grow significantly over the next decade — but clinical de-risking through early human data remains the most critical near-term value driver for companies in this space.

Arovella's use of iNKT cells rather than conventional T cells represents a differentiated biological approach that proponents argue may offer advantages in terms of reduced graft-versus-host disease risk compared to other allogeneic CAR-T platforms.

Risks and What to Watch Next

Phase 1 Clinical Trials carry inherent safety uncertainty, and first-in-human studies by design involve dose escalation under careful oversight, meaning the pace of patient enrolment and dose progression will be managed conservatively. The company is pre-revenue and dependent on Capital Markets for funding through its clinical program. Any safety findings that require dose modifications or trial pauses would be material to the company's development timeline.

Key items to watch include interim safety data expected in early 2027, patient enrolment progression across multiple trial sites, and any further updates on the company's plans to advance ALA-101 into additional indications or expand the CAR-iNKT platform.